Publication | Open Access

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

HepatologyMedicinePathologyLba36 Final AnalysisMolecular OncologyFirst-line TreatmentLiver CancerCancer TreatmentTislelizumab Versus SorafenibOncologyRadiation OncologyHepatocellular CarcinomaCancer Research